Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: A multicenter retrospective study
Số trang: 12
Loại file: pdf
Dung lượng: 1.83 MB
Lượt xem: 10
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-line treatment of ES-SCLC. This retrospective multicenter study aimed to compare the efficacy and safety of anti-PD-1 agents versus anti-PD-L1 agents in first-line treatment of ES-SCLC in real-world practice.
Nội dung trích xuất từ tài liệu:
Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: A multicenter retrospective study
Nội dung trích xuất từ tài liệu:
Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: A multicenter retrospective study
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Small cell lung cancer Anti-PD-1/PD-L1 Locoregional thoracic radiotherapy Lactate dehydrogenase Extensive-stageTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
13 trang 38 0 0